Changes in prices and out-of-pocket costs for brand-name clinician-administered drugs
Using commercial claims data between 2009-2018, a paper in Health Services Research by Lalani et al (2024) finds that: Rebates are rising as a share of cost Fewer patients have $0 out-of-pocket cost Patient out-of-pocket costs growth was 2.9x as large as net drug cost growth Specifically: List prices increased 4.4%/yr (interquartile range [IQR], 1.1%…